Skip to main content
SpringerLink
Log in

Interferon Treatment of Hepatitis C Virus Infection: From Basic Biology to Clinical Application

  • Chapter
Hepatitis C Virus Disease

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Alberti, A., Benvegnu, L. (2003) Management of hepatitis C. Journal of Hepatology, 36: S104–S118.

    Article  Google Scholar 

  • Alric, L., Fort, M., Izopet, J., Vinel, J.P., Charlet, J.P., Selves, J., Puel, J., Pascal, J.P., Duffaut, M., Abbal, M. (1997) Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology, 113: 1675–1681.

    Article  PubMed  CAS  Google Scholar 

  • Annicchiarico, B.E., Siciliano, M. (2004) Pegylated interferon-alpha 2b monotherapy for haemodialysis patients with chronic hepatitis C. Alimentary Pharmacology Therapy, 20: 123–124.

    Article  CAS  Google Scholar 

  • Bennett, W.G., Inoue, Y., Beck, J.R., Wong, J.B., Pauker, S.G., Davis, G.L. (1997) Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Annals of Internal Medicine, 127: 855–865.

    PubMed  CAS  Google Scholar 

  • Berenguer, M., Prieto, M., Rayon, J.M., Mora, J., Pastor, M., Ortiz, V., Carrasco, D., San Juan, F., Burgueno, M.D., Mir, J., Berenguer, J. (2000) Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology, 32: 852–858.

    Article  PubMed  CAS  Google Scholar 

  • Berenguer, M. (2003) Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transplantation, 9: S44–S47.

    Article  PubMed  Google Scholar 

  • Berg, T., Sarrazin, C., Herrmann, E., Hinrichsen, H., Gerlach, T., Zachoval, R., Wiedenmann, B., Hopf, U., Zeuzem, S. (2003) Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology, 37: 600–609.

    Article  PubMed  CAS  Google Scholar 

  • Bloom, R.D., Rao, V., Weng, F., Grossman, R.A., Cohen, D., Mange, K.C. (2002) Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. Journal of the American Society of Nephrology, 13: 1374–1380.

    Article  PubMed  Google Scholar 

  • Brouwer, J.T., Nevens, F., Kleter, B., Elewaut, A., Adler, M., Brenard, R., Chamuleau, R.A., Michielsen, P.P., Pirotte, J., Hautekeete, M.L., Weber, J., Bourgeois, N., Hansen, B.E., Bronkhorst, C.M., ten Kate, F.J., Heijtink, R.A., Fevery, J., Schalm, S.W. (1998) Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. Journal of Hepatology, 28: 951–959.

    Article  PubMed  CAS  Google Scholar 

  • Bruchfeld, A., Lindahl, K., Stahle, L., Soderberg, M., Schvarcz, R. (2003) Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrology Dialysis Transplantation, 18: 1573–1580.

    Article  CAS  Google Scholar 

  • Bruchfeld, A., Wilczek, H., Elinder, C.G. (2004) Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation, 78: 745–750.

    Article  PubMed  Google Scholar 

  • Bruchfeld, A., Lindahl, K., Reichard, O., Carlsson, T., Schvarcz, R. (2006) Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. Journal of Viral Hepatitis, 13: 316–321.

    Article  PubMed  CAS  Google Scholar 

  • Buti, M., Sanchez-Avila, F., Lurie, Y., Stalgis, C., Valdes, A., Martell, M., Esteban, R. (2002) Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alpha-2b plus ribavirin. Hepatology, 35: 930–936.

    Article  PubMed  CAS  Google Scholar 

  • Castro, F.J., Esteban, J.I., Juarez, A., Sauleda, S., Viladomiu, L., Martell, M., Moreno, F., Allende, H., Esteban, R., Guardia, J. (2002) Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C. Journal of Viral Hepatitis, 9: 202–207.

    Article  PubMed  CAS  Google Scholar 

  • Charlton, M. (2003) Natural history of hepatitis C and outcomes following liver transplantation, Clinical Liver Disease, 7: 585–602.

    Article  Google Scholar 

  • Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W., Houghton, M. (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 244: 359–362.

    Article  PubMed  CAS  Google Scholar 

  • Chung, R.T., Andersen, J., Volberding, P., Robbins, G.K., Liu, T., Sherman, K.E., Peters, M.G., Koziel, M.J., Bhan, A.K., Alston, B., Colquhoun, D., Nevin, T., Harb, G., van der Horst, C., AIDS Clinical Trials Group A5071 Study Team (2004) Peginterferon alpha-2a plus ribavirin versus interferon alpha-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. New England Journal of Medicine, 351: 451–459.

    Article  PubMed  CAS  Google Scholar 

  • Corrao, G., Arico, S. (1998) Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology, 27: 914–919.

    Article  PubMed  CAS  Google Scholar 

  • Cramp, M.E., Rossol, S., Chokshi, S., Carucci, P., Williams, R., Naoumov, N.V. (2000) Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology, 118: 346–355.

    Article  PubMed  CAS  Google Scholar 

  • Crosse, K., Umeadi, O.G., Anania, F.A., Laurin, J., Papadimitriou, J., Drachenberg, C., Howell, C.D. (2004) Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clinical Gastroenterology Hepatology, 2: 463–468.

    Article  Google Scholar 

  • Crotty, S., Maag, D., Arnold, J.J., Zhong, W., Lau, J.Y., Hong, Z., Andino, R., Cameron, C.E. (2000) The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Natural Medicine, 6: 1357–1379.

    Google Scholar 

  • Cruzado, J.M., Carrera, M., Torras, J., Grinyo, J.M. (2001) Hepatitis C virus infection and de novo glomerular lesions in renal allografts. American Journal of Transplants, 1: 171–178.

    Article  CAS  Google Scholar 

  • Davis, G.L. (2002) Monitoring of viral levels during therapy of hepatitis C. Hepatology, 36: S145–S145.

    Article  PubMed  Google Scholar 

  • Davis, G.L., Wong, J.B., McHutchison, J.G., Manns, M.P., Harvey, J., Albrecht, J. (2003) Early virologic response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. Hepatology, 38: 645–652.

    Article  PubMed  CAS  Google Scholar 

  • Di Bisceglie, A.M., Conjeevaram, H.S., Fried, M.W., Sallie, R., Park, Y., Yurdaydin, C., Swain, M., Kleiner, D.E., Mahaney, K., Hoofnagle, J.H. (1995) Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine, 123: 897–903.

    PubMed  CAS  Google Scholar 

  • Dienstag, J.L. (2002) The role of liver biopsy in chronic hepatitis C. Hepatology, 36: S152–S160.

    Article  PubMed  Google Scholar 

  • Dienstag, J.L., McHutchison, J.G. (2006) American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology, 130: 225–230.

    Article  PubMed  Google Scholar 

  • Dixit, N.M., Layden-Almer, J.E., Layden, T.J., Perelson, A.S. (2004) Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature, 432: 922–924.

    Article  PubMed  CAS  Google Scholar 

  • Everson, G.T. (2005) Should we treat patients with chronic hepatitis C on the waiting list? Journal of Hepatology, 42: 456–462.

    Article  PubMed  Google Scholar 

  • Fabrizi, F., Poordad, F.F., Martin, P. (2002) Hepatitis C infection and the patient with end-stage renal disease. Hepatology, 36: 3–10.

    Article  PubMed  Google Scholar 

  • Fabrizi, F., Dulai, G., Dixit, V., Bunnapradist, S., Martin, P. (2003) Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Alimentary Pharmacology Therapy, 18: 1071–1081.

    Article  CAS  Google Scholar 

  • Frese, M., Schwarzle, V., Barth, K., Krieger, N., Lohmann, V., Mihm, S., Haller, O., Bartenschlager, R. (2002) Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology, 35: 694–703.

    Article  PubMed  CAS  Google Scholar 

  • Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Goncales, F.L., Jr., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., Yu, J. (2002) Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 347: 975–982.

    Article  PubMed  CAS  Google Scholar 

  • Furusyo, N., Hayashi, J., Ueno, K., Sawayama, Y., Kawakami, Y., Kishihara, Y., Kashiwagi, S. (1997) Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis. Clinical Therapy, 19: 1352–1367.

    Article  CAS  Google Scholar 

  • Furusyo, N., Hayashi, J., Kanamoto-Tanaka, Y., Ariyama, I., Etoh, Y., Shigematsu, M., Kashiwagi, S. (2000a). Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10-year study. Digestive Diseases and Sciences, 45: 2221–2228.

    Article  CAS  Google Scholar 

  • Furusyo, N., Hayashi, J., Ariyama, I., Sawayama, Y., Etoh, Y., Shigematsu, M., Kashiwagi, S. (2000b). Maintenance hemodialysis decreases serum hepatitis C virus (HCV) RNA levels in hemodialysis patients with chronic HCV infection. American Journal of Gastroenterology, 95: 490–496.

    Article  CAS  Google Scholar 

  • Furusyo, N., Hayashi, J., Kakuda, K., Ariyama, I., Kanamoto-Tanaka, Y., Shimizu, C., Etoh, Y., Shigematsu, M., Kashiwagi, S. (2001) Acute hepatitis C among Japanese hemodialysis patients: a prospective 9-year study. American Journal of Gastroenterology, 96: 1592–1600.

    Article  PubMed  CAS  Google Scholar 

  • Furusyo, N., Hayashi, J., Kashiwagi, K., Nakashima, H., Nabeshima, S., Sawayama, Y., Kinukawa, N., Kashiwagi, S. (2002) Hepatitis C virus (HCV) RNA level determined by second-generation branched-DNA probe assay as predictor of response to interferon treatment in patients with chronic HCV viremia. Digestive Diseases and Sciences, 47: 535–542.

    Article  PubMed  CAS  Google Scholar 

  • Furusyo, N., Kubo, N., Nakashima, H., Kashiwagi, K., Etoh, Y., Hayashi, J. (2004) Confirmation of nosocomial hepatitis C virus infection in a hemodialysis unit. Infection Control in Hospital Epidemiology, 25: 584–590.

    Article  Google Scholar 

  • Furusyo, N., Kubo, N., Toyoda, K., Takeoka, H., Nabeshima, S., Murata, M., Nakamuta, M., Hayashi, J. (2005) Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C. Antiviral Research, 67: 46–54.

    Article  PubMed  CAS  Google Scholar 

  • Furusyo, N., Katoh, M., Tanabe, Y., Kajiwara, E., Maruyama, T., Shimono, J., Sakai, H., Nakamuta, M., Nomura, H., Masumoto, A., Shimoda, S., Takahashi, K., Azuma, K., Hayashi, J. (2006) Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group. World Journal of Gastroenterology, 12: 784–790.

    PubMed  CAS  Google Scholar 

  • Gane, E. (2002) Treatment of recurrent hepatitis C. Liver Transplantation, 8: S28–S37.

    Article  PubMed  Google Scholar 

  • Ghany, M.G., Kleiner, D.E., Alter, H., Doo, E., Khokar, F., Promrat, K., Herion, D., Park, Y., Liang, T.J., Hoofnagle, J.H. (2003) Progression of fibrosis in chronic hepatitis C. Gastroenterology, 124: 97–104.

    Article  PubMed  Google Scholar 

  • Hadziyannis, S.J., Sette, H., Jr., Morgan, T.R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Jr., Bernstein, D., Rizzetto, M., Zeuzem, S., Pockros, P.J., Lin, A., Ackrill, A.M., PEGASYS International Study Group (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine, 140: 346–355.

    PubMed  CAS  Google Scholar 

  • Hagiwara, H., Hayashi, N., Mita, E., Ueda, K., Takehara, T., Kasahara, A., Fusamoto, H., Kamada, T. (1992) Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha. Hepatology, 15: 37–41.

    Article  PubMed  CAS  Google Scholar 

  • Hayashi, J., Hirata, M., Nakashima, K., Noguchi, A., Kashiwagi, S., Matsui, M., Ishibashi, H., Maeda, Y. (1991a). Hepatitis C virus is a more likely cause of chronic liver disease in the Japanese population than hepatitis B virus. Fukuoka Igaku Zasshi, 82: 648–654.

    CAS  Google Scholar 

  • Hayashi, J., Nakashima, K., Kajiyama, W., Noguchi, A., Morofuji, M., Maeda, Y., Kashiwagi, S. (1991b). Prevalence of antibody to hepatitis C virus in hemodialysis patients. American Journal of Epidemiology, 134: 651–657.

    CAS  Google Scholar 

  • Hayashi, J., Ohmiya, M., Kishihara, Y., Tani, Y., Kinukawa, N., Ikematsu, H., Kashiwagi, S. (1994a). A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. American Journal of Gastroenterology, 89: 2151–2156.

    CAS  Google Scholar 

  • Hayashi, J., Nakashima, K., Yoshimura, E., Kishihara, Y., Ohmiya, M., Hirata, M., Kashiwagi, S. (1994b). Prevalence and role of hepatitis C viraemia in haemodialysis patients in Japan. Journal of Infection, 28: 271–277.

    Article  CAS  Google Scholar 

  • Hayashi, J., Kishihara, Y., Yamaji, K., Furusyo, N., Yamamoto, T., Pae, Y., Etoh, Y., Ikematsu, H., Kashiwagi, S. (1997a). Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection. Hepatology, 25: 697–701.

    Article  CAS  Google Scholar 

  • Hayashi, J., Kishihara, Y., Yoshimura, E., Furusyo, N., Yamaji, K., Kawakami, Y., Murakami, H., Kashiwagi, S. (1997b). Correlation between human T cell lymphotropic virus type-1 and Strongyloides stercoralis infections and serum immunoglobulin E responses in residents of Okinawa, Japan. American Journal of Tropical Medicine Hygiene, 56: 71–75.

    CAS  Google Scholar 

  • Hayashi, J., Kishihara, Y., Ueno, K., Yamaji, K., Kawakami, Y., Furusyo, N., Sawayama, Y., Kashiwagi, S. (1998a). Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Archives of Internal Medicine, 158: 177–181.

    Article  CAS  Google Scholar 

  • Hayashi, J., Kawakami, Y., Nabeshima, A., Kishihara, Y., Furusyo, N., Sawayama, Y., Kinukawa, N., Kashiwagi, S. (1998b). Comparison of HCV RNA levels by branched DNA probe assay and by competitive polymerase chain reaction to predict effectiveness of interferon treatment for patients with chronic hepatitis C virus. Digestive Diseases and Sciences, 43: 384–391.

    Article  CAS  Google Scholar 

  • Hayashi, J., Furusyo, N., Ariyama, I., Sawayama, Y., Etoh, Y., Kashiwagi, S. (2000) A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia. Journal of Infectious Disease, 181: 1523–1527.

    Article  CAS  Google Scholar 

  • Heathcote, E.J., Shiffman, M.L., Cooksley, W.G., Dusheiko, G.M., Lee, S.S., Balart, L., Reindollar, R., Reddy, R.K., Wright, T.L., Lin, A., Hoffman, J., De Pamphilis, J. (2000) Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis. New England Journal of Medicine, 343: 1673–1680.

    Article  PubMed  CAS  Google Scholar 

  • Hoofnagle, J.H., Mullen, K.D., Jones, D.B., Rustgi, V., Di Bisceglie, A., Peters, M., Waggoner, J.G., Park, Y., Jones, E.A. (1986) Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. New England Journal of Medicine, 315: 1575–1578.

    Article  PubMed  CAS  Google Scholar 

  • Hoofnagle, J.H., Lau, D., Conjeevaram, H., Kleiner, D., Di Bisceglie, A.M. (1996) Prolonged therapy of chronic hepatitis C with ribavirin. Journal of Viral Hepatology, 3: 247–252.

    CAS  Google Scholar 

  • Hourigan, L.F., Macdonald, G.A., Purdie, D., Whitehall, V.H., Shorthouse, C., Clouston, A., Powell, E.E. (1999) Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology, 29: 1215–1219.

    Article  PubMed  CAS  Google Scholar 

  • Hugle, T., Cerny, A. (2003) Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C. Reviews in Medical Virology., 13: 361–371.

    Article  PubMed  CAS  Google Scholar 

  • Jaeckel, E., Cornberg, M., Wedemeyer, H., Santantonio, T., Mayer, J., Zankel, M., Pastore, G., Dietrich, M., Trautwein, C., Manns, M.P., German Acute Hepatitis C Therapy Group (2001) Treatment of acute hepatitis C with interferon alpha-2b. New England Journal of Medicine, 345: 1452–1457.

    Google Scholar 

  • Kasahara, A., Hayashi, N., Mochizuki, K., Takayanagi, M., Yoshioka, K., Kakumu, S., Iijima, A., Urushihara, A., Kiyosawa, K., Okuda, M., Hino, K., Okita, K. (1998) Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology, 27: 1394–1402.

    Article  PubMed  CAS  Google Scholar 

  • Kashiwagi, S., Kajiyama, W., Hayashi, J., Noguchi, A., Nakashima, K., Nomura, H., Ikematsu, H., Sawada, T., Kida, S., Koide, A. (1990) Antibody to p40tax protein of human T cell leukemia virus 1 and infectivity. Journal of Infectious Diseases, 161: 426–429.

    PubMed  CAS  Google Scholar 

  • Kashiwagi, K., Furusyo, N., Kubo, N., Nakashima, H., Nomura, H., Kashiwagi, S., Hayashi, J. (2003) A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development. Journal of Infection and Chemotherapy, 9: 333–340.

    Article  PubMed  CAS  Google Scholar 

  • Kawakami, Y., Nabeshima, S., Furusyo, N., Sawayama, Y., Hayashi, J., Kashiwagi, S. (2000) Increased frequency of interferon-gamma-producing peripheral blood CD4+ T cells in chronic hepatitis C virus infection. American Journal of Gastroenterology, 95: 227–232.

    PubMed  CAS  Google Scholar 

  • Kirchner, H. (1984) Interferons, a group of multiple lymphokines. Springer Seminar in Immunopathology, 7: 347–374.

    CAS  Google Scholar 

  • Kishihara, Y., Furusyo, N., Kashiwagi, K., Mitsutake, A., Kashiwagi, S., Hayashi, J. (2001) Human T lymphotropic virus type 1 infection influences hepatitis C virus clearance. Journal of Infectious Disease, 184: 1114–1119.

    Article  CAS  Google Scholar 

  • Kottilil, S., Polis, M.A., Kovacs, J.A. (2004) HIV Infection, hepatitis C infection, and HAART: hard clinical choices. The Journal of the American Medical Association, 292: 243–250.

    Article  CAS  Google Scholar 

  • Kubo, N., Furusyo, N., Nakashima, H., Kashiwagi, K., Hayashi, J. (2005) Strenuous physical labor is important as a cause of elevated alanine aminotransferase levels in Japanese patients with chronic hepatitis C viremia. European Journal of Epidemiology, 20: 251–261.

    Article  PubMed  CAS  Google Scholar 

  • Lafeuillade, A., Hittinger, G., Chadapaud, S. (2001) Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet, 357: 280–281.

    Article  PubMed  CAS  Google Scholar 

  • Laskus, T., Radkowski, M., Wang, L.F., Jang, S.J., Vargas, H., Rakela, J. (1998) Hepatitis C virus quasispecies in patients infected with HIV-1: correlation with extrahepatic viral replication. Virology, 248: 164–171.

    Article  PubMed  CAS  Google Scholar 

  • Lau, D.T., Kleiner, D.E., Ghany, M.G., Park, Y., Schmid, P., Hoofnagle, J.H. (1998) 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology, 28: 1121–1127.

    Article  PubMed  CAS  Google Scholar 

  • Lau, J.Y., Tam, R.C., Liang, T.J., Hong, Z. (2002) Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology, 35: 1002–1009.

    Article  PubMed  CAS  Google Scholar 

  • Layden-Almer, J.E., Ribeiro, R.M., Wiley, T., Perelson, A.S., Layden, T.J. (2003) Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology, 37: 1343–1350.

    Article  PubMed  CAS  Google Scholar 

  • Liang, T.J., Rehermann, B., Seeff, L.B., Hoofnagle, J.H. (2000) Pathogenesis, natural history, treatment, and prevention of hepatitis C. Annals of Internal Medicine, 132: 296–305.

    PubMed  CAS  Google Scholar 

  • Lindsay, K.L., Trepo, C., Heintges, T., Shiffman, M.L., Gordon, S.C., Hoefs, J.C., Schiff, E.R., Goodman, Z.D., Laughlin, M., Yao, R., Albrecht, J.K., Hepatitis Interventional Therapy Group (2001) A randomized, double-blind trial comparing pegylated interferon alpha-2b to interferon alpha-2b as initial treatment for chronic hepatitis C. Hepatology, 34: 395–403.

    Google Scholar 

  • Luxon, B.A., Grace, M., Brassard, D., Bordens, R. (2002) Pegylated interferons for the treatment of chronic hepatitis C infection. Clinical Therapy, 24: 1363–1383.

    Article  CAS  Google Scholar 

  • Mangia, A., Santoro, R., Minerva, N., Ricci, G.L., Carretta, V., Persico, M., Vinelli, F., Scotto, G., Bacca, D., Annese, M., Romano, M., Zechini, F., Sogari, F., Spirito, F., Andriulli, A. (2005) Peginterferon alpha-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. New England Journal of Medicine, 352: 2609–2617.

    Article  PubMed  CAS  Google Scholar 

  • Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M., Albrecht, J.K. (2001) Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 358: 958–965.

    Article  PubMed  CAS  Google Scholar 

  • Marcellin, P., Boyer, N., Degott, C., Martinot-Peignoux, M., Duchatelle, V., Giostra, E., Areias, J., Erlinger, S., Benhamou, J.P. (1994) Long-term histologic and viral changes in patients with chronic hepatitis C who responded to alpha interferon. Liver, 14: 302–307.

    PubMed  CAS  Google Scholar 

  • Marcellin, P., Boyer, N., Gervais, A., Martinot, M., Pouteau, M., Castelnau, C., Kilani, A., Areias, J., Auperin, A., Benhamou, J.P., Degott, C., Erlinger, S. (1997) Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Annals of Internal Medicine, 127: 875–881.

    PubMed  CAS  Google Scholar 

  • McHutchison, J.G., Gordon, S.C., Schiff, E.R., Shiffman, M.L., Lee, W.M., Rustgi, V.K., Goodman, Z.D., Ling, M.H., Cort, S., Albrecht, J.K. (1998) Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New England Journal of Medicine, 339: 1485–1492.

    Article  PubMed  CAS  Google Scholar 

  • Mohsen, A.H., Easterbrook, P.J., Taylor, C., Portmann, B., Kulasegaram, R., Murad, S., Wiselka, M., Norris, S. (2003) Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut, 52: 1035–1040.

    Article  PubMed  CAS  Google Scholar 

  • Monga, H.K., Rodriguez-Barradas, M.C., Breaux, K., Khattak, K., Troisi, C.L., Velez, M., Yoffe, B. (2001) Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clinical Infectious Disease, 33: 240–247.

    Article  CAS  Google Scholar 

  • Muir, A.J., Bornstein, J.D., Killenberg, P.G., Atlantic Coast Hepatitis Treatment Group (2004) Peginterferon alpha-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. New England Journal of Medicine, 350: 2265–2271.

    Google Scholar 

  • Murata, M., Nabeshima, S., Maeda, N., Nakashima, H., Kashiwagi, S., Hayashi, J. (2002) Increased frequency of IFN-gamma-producing peripheral CD8+ T cells with memory-phenotype in patients with chronic hepatitis C. Journal of Medical Virology, 67: 162–170.

    Article  PubMed  Google Scholar 

  • Murata, M., Nabeshima, S., Kikuchi, K., Yamaji, K., Furusyo, N., Hayashi, J. (2006) A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines. Cytokine, 33: 121–128.

    Article  PubMed  CAS  Google Scholar 

  • National Institutes of Health Consensus Development Conference statement (2002) Management of Hepatitis C: 2002-June 10–12, 2002. Hepatology, 36: S3–S20.

    Google Scholar 

  • Neumann, A.U., Lam, N.P., Dahari, H., Gretch, D.R., Wiley, T.E., Layden, T.J., Perelson, A.S. (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science, 282: 103–107.

    Article  PubMed  CAS  Google Scholar 

  • Niederau, C., Lange, S., Heintges, T., Erhardt, A., Buschkamp, M., Hurter, D., Nawrocki, M., Kruska, L., Hensel, F., Petry, W., Haussinger, D. (1998) Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology, 28: 1687–1695.

    Article  PubMed  CAS  Google Scholar 

  • Nishiguchi, S., Kuroki, T., Nakatani, S., Morimoto, H., Takeda, T., Nakajima, S., Shiomi, S., Seki, S., Kobayashi, K., Otani, S. (1995) Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet, 346: 1051–1055.

    Article  PubMed  CAS  Google Scholar 

  • Nomura, H., Tanimoto, H., Kajiwara, E., Shimono, J., Maruyama, T., Yamashita, N., Nagano, M., Higashi, M., Mukai, T., Matsui, Y., Hayashi, J., Kashiwagi, S., Ishibashi, H. (2004a). Factors contributing to ribavirin-induced anemia. Journal of Gastroenterology and Hepatology, 19: 1312–1317.

    Article  CAS  Google Scholar 

  • Nomura, H., Sou, S., Tanimoto, H., Nagahama, T., Kimura, Y., Hayashi, J., Ishibashi, H., Kashiwagi, S. (2004b). Short-term interferon-alpha therapy for acute hepatitis C: a randomized controlled trial. Hepatology, 39: 1213–1219.

    Article  CAS  Google Scholar 

  • Okanoue, T., Itoh, Y., Minami, M., Sakamoto, S., Yasui, K., Sakamoto, M., Nishioji, K., Murakami, Y., Kashima K. (1999) Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. Journal of Hepatology, 30: 653–659.

    Article  PubMed  CAS  Google Scholar 

  • Pereira, B.J., Natov, S.N., Bouthot, B.A., Murthy, B.V., Ruthazer, R., Schmid, C.H., Levey, A.S. (1998) Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney International, 53: 1374–1381.

    Article  PubMed  CAS  Google Scholar 

  • Perez-Olmeda, M., Nunez, M., Romero, M., Gonzalez, J., Castro, A., Arribas, J.R., Pedreira, J., Barreiro, P., Garcia-Samaniego, J., Martin-Carbonero, L., Jimenez-Nacher, I., Soriano, V. (2003) Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS, 17: 1023–1028.

    Article  PubMed  CAS  Google Scholar 

  • Poynard, T., Bedossa, P., Chevallier, M., Mathurin, P., Lemonnier, C., Trepo, C., Couzigou, P., Payen, J.L., Sajus, M., Costa, J.M. (1995) A comparison of three interferon alpha-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. New England Journal of Medicine, 332: 1457–1462.

    Article  PubMed  CAS  Google Scholar 

  • Poynard, T., Leroy, V., Cohard, M., Thevenot, T., Mathurin, P., Opolon, P., Zarski, J.P. (1996) Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology, 24: 778–789.

    Article  PubMed  CAS  Google Scholar 

  • Poynard, T., Bedossa, P., Opolon, P. (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet, 349: 825–832.

    Article  PubMed  CAS  Google Scholar 

  • Poynard, T., Marcellin, P., Lee, S.S., Niederau, C., Minuk, G.S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., Albrecht, J. (1998) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet, 352: 1426–1432.

    Article  PubMed  CAS  Google Scholar 

  • Reddy, K.R., Wright, T.L., Pockros, P.J., Shiffman, M., Everson, G., Reindollar, R., Fried, M.W., Purdum, P.P. 3rd., Jensen, D., Smith, C., Lee, W.M., Boyer, T.D., Lin, A., Pedder, S., DePamphilis, J. (2001) Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology, 33: 433–438.

    Article  PubMed  CAS  Google Scholar 

  • Robertson, B., Myers, G., Howard, C., Brettin, T., Bukh, J., Gaschen, B., Gojobori, T., Maertens, G., Mizokami, M., Nainan, O., Netesov, S., Nishioka, K., Shini, T., Simmonds, P., Smith, D., Stuyver, L., Weiner, A. (1998) Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: Proposals for standardization. International Committee on Virus Taxonomy. Archives of Virology, 143: 2493–2503.

    Article  PubMed  CAS  Google Scholar 

  • Rodriguez-Luna, H., Khatib, A., Sharma, P., De Petris, G., Williams, J.W., Ortiz, J., Hansen, K., Mulligan, D., Moss, A., Douglas, D.D., Balan, V.. Rakela, J., Vargas, H.E. (2004) Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation, 77: 190–194.

    Article  PubMed  CAS  Google Scholar 

  • Russo, M.W., Goldsweig, C.D., Jacobson, I.M., Brown, R.S., Jr. (2003) Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. American Journal of Gastroenterology, 98: 1610–1615.

    Article  PubMed  CAS  Google Scholar 

  • Sanchez-Tapias, J.M., Diago, M., Escartin, P., Enriquez, J., Romero-Gomez, M., Barcena, R., Crespo, J., Andrade, R., Martinez-Bauer, E., Perez, R., Testillano, M., Planas, R., Sola, R., Garcia-Bengoechea, M., Garcia-Samaniego, J., Munoz-Sanchez, M., Moreno-Otero, R., TeraViC-4 Study Group (2006) Peginterferon-alpha2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology, 131: 451–460.

    Article  PubMed  CAS  Google Scholar 

  • Scott, L.J., Perry, C.M. (2002) Interferon-alpha-2b plus ribavirin: A review of its use in the management of chronic hepatitis C. Drugs, 62: 507–556.

    Article  PubMed  CAS  Google Scholar 

  • Sheeff, L.B., Hoofnagle, J.H. (2002) National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology, 36: S1–S2.

    Google Scholar 

  • Shiffman, M.L., Di Bisceglie, A.M., Lindsay, K.L., Morishima, C., Wright, E.C., Everson, G.T., Lok, A.S., Morgan, T.R., Bonkovsky, H.L., Lee, W.M., Dienstag, J.L., Ghany, M.G., Goodman, Z.D., Everhart, J.E., Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group (2004) Peginterferon alpha-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology, 126: 1015–1023.

    Google Scholar 

  • Shindo, M., Di Bisceglie, A.M., Cheung, L., Shih, J.W., Cristiano, K., Feinstone, S.M., Hoofnagle, J.H. (1991) Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Annals of Internal Medicine, 115: 700–704.

    PubMed  CAS  Google Scholar 

  • Soza, A., Heller, T., Ghany, M., Lutchman, G., Jake Liang, T., Germain, J., Hsu, H.H., Park, Y., Hoofnagle, J.H. (2005) Pilot study of interferon gamma for chronic hepatitis C. Journal of Hepatology, 43: 67–71.

    Article  PubMed  CAS  Google Scholar 

  • Sporea, I., Sirli, R., Golea, O., Totolici, C., Danila, M., Popescu, A. (2004) Peg-interferon alpha 2a (40kDa) in patients on chronic haemodialysis with chronic C hepatitis. Preliminary results. Roman Journal of Gastroenterology, 13: 99–102.

    Google Scholar 

  • Strader, D.B., Wright, T., Thomas, D.L., Seeff, L.B., American Association for the Study of Liver Diseases (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology, 39: 1147–1171.

    Google Scholar 

  • Thomas, D.L., Astemborski, J., Rai, R.M., Anania, F.A., Schaeffer, M., Galai, N., Nolt, K., Nelson, K.E., Strathdee, S.A., Johnson, L., Laeyendecker, O., Boitnott, J., Wilson, L.E., Vlahov, D. (2000) The natural history of hepatitis C virus infection: host, viral, and environmental factors, The Journal of the American Medical Association, 284: 450–456.

    Article  CAS  Google Scholar 

  • Tilg, H. (1997) New insights into the mechanisms of interferon alpha: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology, 112: 1017–1021.

    Article  PubMed  CAS  Google Scholar 

  • Torriani, F.J., Rodriguez-Torres, M., Rockstroh, J.K., Lissen, E., Gonzalez-Garcia, J., Lazzarin, A., Carosi, G., Sasadeusz, J., Katlama, C., Montaner, J., Sette, H., Jr., Passe, S., De Pamphilis, J., Duff, F., Schrenk, U.M., Dieterich, D.T., APRICOT Study Group (2004) Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New England Journal of Medicine, 351: 438–450.

    Article  PubMed  CAS  Google Scholar 

  • Yamaji, K., Hayashi, J., Kawakami, Y., Furusyo, N., Sawayama, Y., Kishihara, Y., Etoh, Y., Kashiwagi, S. (1998) Hepatitis C viral RNA status at two weeks of therapy predicts the eventual response. Journal of Clinical Gastroenterology, 26: 193–199.

    Article  PubMed  CAS  Google Scholar 

  • Yano, M., Kumada, H., Kage, M., Ikeda, K., Shimamatsu, K., Inoue, O., Hashimoto, E., Lefkowitch, J.H., Ludwig, J., Okuda, K. (1996) The long-term pathological evolution of chronic hepatitis C. Hepatology, 23: 1334–1340.

    Article  PubMed  CAS  Google Scholar 

  • Yoshida, H., Shiratori, Y., Moriyama, M., Arakawa, Y., Ide, T., Sata, M., Inoue, O., Yano, M., Tanaka, M., Fujiyama, S., Nishiguchi, S., Kuroki, T., Imazeki, F., Yokosuka, O., Kinoyama, S, Yamada, G., Omata, M. (1999) Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Annals of Internal Medicine, 131: 174–181.

    PubMed  CAS  Google Scholar 

  • Zeuzem, S., Schmidt, J.M., Lee, J.H., von Wagner, M., Teuber, G., Roth, W.K. (1998) Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alpha on viral turnover. Hepatology, 28: 245–252.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Medicine, Kyushu University Hospital, Higashi-Ku, Fukuoka 812-8582, Japan

    Norihiro Furusyo (Associate Professor)

Authors
  1. Norihiro Furusyo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masayuki Murata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jun Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Bari and National Institute for Digestive Disease, Castellana Grotte, Bari, Italy

    Emilio Jirillo

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Furusyo, N., Murata, M., Hayashi, J. (2008). Interferon Treatment of Hepatitis C Virus Infection: From Basic Biology to Clinical Application. In: Jirillo, E. (eds) Hepatitis C Virus Disease. Springer, New York, NY. https://doi.org/10.1007/978-0-387-71376-2_8

Download citation

Publish with us

Policies and ethics

Search

Navigation